A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

Inclusion Criteria:

• Has a diagnosis of ET per WHO 2016 diagnostic criteria for myeloproliferativeneoplasms (confirmed by a central pathologist)

• Has a centrally assessed bone marrow fibrosis score of Grade 0 or Grade 1, as per amodified version of the European Consensus Criteria for Grading Myelofibrosis

• Has a history of inadequate response to or intolerance of hydroxyurea based onmodified European LeukemiaNet (ELN) criteria for hydroxyurea resistance orintolerance

• Has an inadequate or loss of response to their most recent prior ET therapy,requiring a change of cytoreductive therapy

• Has a platelet count > 450 × 10^9/L (450k /μL) assessed up to 72 hours before firstdose of study intervention

• Has an absolute neutrophil count (ANC) ≥0.75 × 10^9/L assessed up to 72 hours beforefirst dose of study intervention

• Participants may have received up to 3 prior ET-directed cytoreductive agentsincluding hydroxyurea

Exclusion Criteria:

• Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugschemically related to bomedemstat or lysine demethylase or monoamine oxidaseinhibitor (LSDi or MAOi) or the chosen best available therapy (including anagrelide,interferon alfa/pegylated interferon, ruxolitinib, or busulfan) that contraindicatesparticipation

• History of any illness/impairment of GI function that might interfere with drugabsorption (eg, chronic diarrhea or history of gastric bypass surgical procedure),confound the study results or pose an additional risk to the individual byparticipation in the study

• Evidence at the time of Screening of increased risk of bleeding

• History of a malignancy, unless potentially curative treatment has been completedwith no evidence of malignancy for 2 years. Note: The time requirement does notapply to participants who underwent successful definitive resection of basal cellcarcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ,excluding carcinoma in situ of the bladder

• Human immunodeficiency virus (HIV)-infected participants with a history of Kaposi'ssarcoma and/or Multicentric Castleman's Disease